{
  "id": "61f608d4882a024a10000023",
  "type": "yesno",
  "question": "Is sacituzumab govitecan effective for breast cancer?",
  "ideal_answer": "Yes. Sacituzumab Govitecan  is a new and available treatment for metastatic triple-negative breast cancer.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/34176192",
    "http://www.ncbi.nlm.nih.gov/pubmed/32529410",
    "http://www.ncbi.nlm.nih.gov/pubmed/33882206",
    "http://www.ncbi.nlm.nih.gov/pubmed/31584574",
    "http://www.ncbi.nlm.nih.gov/pubmed/34404686",
    "http://www.ncbi.nlm.nih.gov/pubmed/34761708",
    "http://www.ncbi.nlm.nih.gov/pubmed/26577300",
    "http://www.ncbi.nlm.nih.gov/pubmed/33187148",
    "http://www.ncbi.nlm.nih.gov/pubmed/34651524",
    "http://www.ncbi.nlm.nih.gov/pubmed/34671504",
    "http://www.ncbi.nlm.nih.gov/pubmed/31398063",
    "http://www.ncbi.nlm.nih.gov/pubmed/30507322",
    "http://www.ncbi.nlm.nih.gov/pubmed/30867160",
    "http://www.ncbi.nlm.nih.gov/pubmed/28291390",
    "http://www.ncbi.nlm.nih.gov/pubmed/34467774",
    "http://www.ncbi.nlm.nih.gov/pubmed/34688044",
    "http://www.ncbi.nlm.nih.gov/pubmed/33816696"
  ],
  "snippets": [
    {
      "text": "Sacituzumab Govitecan (also known by the brand name TRODELVY\u00ae) is a new and available treatment for metastatic triple-negative breast cancer, or mTNBC for short. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34467774",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sacituzumab govitecan (sacituzumab govitecan-hziy; Trodelvy\u2122) is a Trop-2-directed antibody conjugated to a topoisomerase I inhibitor (SN-38) that is being developed by Immunomedics for the treatment of solid tumours, including breast cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32529410",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Results from a phase I/II trial suggest that an antibody-drug conjugate, sacituzumab govitecan, is active against refractory, metastatic triple-negative breast cancer. A",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30867160",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTRODUCTION: Sacituzumab govitecan-hziy, approved in 2020 for treatment of metastatic triple-negative breast cancer, provides a new option for a population with a historically poor prognosis with standard ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34761708",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sacituzumab govitecan (SG), the first antibody-drug conjugate (ADC) approved for triple-negative breast cancer, incorporates the anti-TROP2 antibody hRS7 conjugated to a topoisomerase-1 (TOP1) inhibitor payload. We so",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34404686",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sacituzumab govitecan was initially approved in April 2020 under accelerated approval for the treatment of patients with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34671504",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The ASCENT trial reports impressive results with a median overall survival (OS) increased from 6.7 months to 12.1 months with sacituzumab govitecan over single-agent chemotherapy, in metastatic triple negative breast cancer (TNBC) patients in second and subsequent line of therapy. We ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34688044",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A phase II study indicates that sacituzumab govitecan (IMMU-132), a Trop-2-specific antibody linked to the irinotecan metabolite SN-38, prolongs the progression-free survival of patients with advanced triple-negative breast cancer. I",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26577300",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "agents, sacituzumab govitecan, has been recently granted an accelerated approval for therapy of metastatic triple-negative breast cancer. In this artic",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33187148",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "l 2020, sacituzumab govitecan received accelerated approval in the USA for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease. Sacituzu",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32529410",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34176192",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "ood and Drug Administration) recently approved the use of a Trop2-targeting ADC (antibody-drug conjugate), Sacituzumab Govitecan (IMMU-132), for metastatic, triple-negative breast cancer with at least two prior therapies. Here, we review",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33816696",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "sive disease. Sacituzumab govitecan represents an important advance in the treatment of mTNBC because of its efficacy an",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30507322",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sacituzumab govitecan (SG) is a novel antibody-drug conjugate (ADC) that has shown promising efficacy in mTNBC",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31584574",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The activity of sacituzumab govitecan likely extends beyond TNBC with promising early efficacy data in many other epithelial cancers, including hormone receptor-positive breast cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31398063",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In a basket design phase I/II study, sacituzumab govitecan demonstrated promising single-agent therapeutic activity in multiple cancer cohorts, leading to accelerated approval by the U.S. Food and Drug Administration of sacituzumab govitecan-hziy (TRODELVY) for the treatment of patients with metastatic triple-negative breast cancer who had received at least two prior therapies in the metastatic setting.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34176192",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28291390",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Expert opinion: Sacituzumab govitecan has promising anti-cancer activity in patients with metastatic TNBC previously treated with at least two prior lines of systemic therapy based on a single arm Phase I/II clinical trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31398063",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sacituzumab govitecan has shown promise in cancers outside of TNBC, such as urothelial and lung and is being evaluated in HR-positive breast cancers.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34651524",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " prognosis. Sacituzumab govitecan is an antibody-drug conjugate composed of an antibody targeting the human trophoblast cell-surface antigen 2 (Trop-2), which is expressed in the majority of breast cancers, coupled to SN-38 (topoisomerase I inhibitor) through a proprietary hydrolyzable linker.METHODS: In this randomized, phase 3 trial, we evaluated sacituzumab govitecan as compared with single-agent chemotherapy of the physician's choice (eribulin, vinorelbine, capecitabine, or gemcitabine) in patients with relapsed or refractory metastatic triple-ne",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33882206",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Expert opinion Sacituzumab govitecan has promising survival benefits in patients with previously treated mTNBC based on data from the ASCENT trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34651524",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Conclusion Sacituzumab govitecan was well tolerated and induced early and durable responses in heavily pretreated patients with metastatic TNBC.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28291390",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33882206",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Sacituzumab Govitecan (also known by the brand name TRODELVY\u00ae) is a new and available treatment for metastatic triple-negative breast cancer, or mTNBC for short.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34467774",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}